Stock is currently well below the average analyst price target of $18 and a BUY rating.
Zynerba Pharmaceuticals , Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on research and development of rare and near-rare neuropsychiatric conditions. It offers Zygel product which formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.
I would be very careful to place a trade this week.
Check out https://www.ftserussell.com/resources/russell-reconstitution for the Russell reconstitution.